Chemours Company (The) (CC) Stock Price & How to Invest

The Chemours Company is a US-listed specialty chemicals producer spun out of DuPont in 2015. It reports through three segments: Thermal & Specialized Solutions (refrigerants and thermal management, led by the Opteon low-global-warming-potential product line), Titanium Technologies (TiO2 white pigment used in paints, plastics, and paper), and Advanced Performance Materials (high-end fluoropolymers and advanced materials). Full-year 2025 net sales were roughly $5.8 billion, and the company operates globally across industrial, construction, automotive, and electronics end markets.

The investment picture is a barbell. Opteon refrigerants are benefiting from the regulatory phase-down of higher-emission HFCs under the AIM Act, giving Chemours a structurally growing, higher-margin franchise. Against that, the Titanium Technologies business is deeply cyclical and has faced soft pricing and demand tied to construction and coatings, while the company carries substantial, widely reported PFAS environmental and litigation liabilities. Chemours reached a $450 million EPA and DOJ settlement in June 2026 covering several legacy facilities, but AFFF multi-district litigation and other claims remain unresolved, keeping the balance sheet and legal exposure central to how the stock trades.

PFAS environmental litigation and remediation are the defining risk: Chemours faces thousands of personal injury claims in the AFFF multi-district litigation with bellwether trials that could produce unpredictable damages, on top of the $450 million EPA and DOJ settlement already reached in 2026. The Titanium Technologies segment is cyclical and exposed to weak construction and coatings demand plus low-cost pigment competition. The company posted a net loss in Q1 2026, underscoring thin profitability. Leverage and the cash demands of legal settlements constrain financial flexibility. Regulatory, raw-material, and currency swings add further volatility to results.

A simple financial snapshot. These are approximations and refresh quarterly; for current figures see Chemours Company (The)'s investor relations page or your broker.

• Revenue (FY2025): ~$5.8B
• Q1 2026 revenue: ~$1.38B
• Q1 2026 net loss: ~$29M
• 2026 adj. EBITDA guide: ~$800-900M
• Market cap: ~$3.3B
• Dividend yield: ~1.5%

Chemours trades at a low equity valuation relative to its ~$5.8 billion revenue base, reflecting cyclical earnings and PFAS liability overhang rather than a high-growth multiple. Q1 2026 showed revenue up modestly year over year but a net loss, with 2026 guidance calling for 3 to 5 percent sales growth. EV/EBITDA has run in the low-to-mid teens, so much of the enterprise value sits in debt and litigation obligations.

There are three common ways to get CC exposure. Buy shares (or fractional shares) directly at any major broker. Hold an ETF that includes it, which spreads the position across many companies. Or build it into a focused thematic basket, so CC sits alongside other stocks that express the same thesis.

Walnut takes the basket route. Describe a thesis where CC fits (for example “AI infrastructure” or “dividend-growth large-caps”) and the AI proposes 5 to 6 constituents with target weights. You review the plan and fund it through your own broker when you're ready.

CC is a cyclical chemicals company with a genuine refrigerant growth engine offset by weak TiO2 pricing and sizable, well-publicized PFAS liabilities.

Whether CC is worth buying today depends more on your time horizon and what you already hold than on any single call. We walk through valuation, what would have to go right, and the risks in is CC a buy?, and where the stock could go from here in the CC stock forecast.

For income investors, whether CC pays a dividend and how the payout looks is covered in does CC pay a dividend?